CTLA4 and sarcoidosis: In cancer patients, treatment with both anti-CTLA-4 and PD-1/PD-L1 inhibitors is associated with an increase in Th17 cells [103–105], so there is not enough evidence for the use of immune checkpoint inhibitors in sarcoidosis, particularly given the likely importance of Th17 cells in progression of sarcoidosis.